ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia K-562 cells, short-term imatinib treatment induced ABCG2 expression and decreased miR-212 expression, while anti-miR-212 upregulated ABCG2 protein expression by direct targeting ABCG2 3’-UTR [61].